A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-15
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, controlled, two-part study to evaluate the safety and efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.